We have collected information about Port Delivery System Ranibizumab for you. Follow the links to find out details on Port Delivery System Ranibizumab.
https://clinicaltrials.gov/ct2/show/NCT02510794
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER) - Full Text View.
https://www.sciencedirect.com/science/article/pii/S0161642018333281
The Port Delivery System with ranibizumab (PDS) is a novel, innovative, long-acting drug delivery system with the potential to reduce treatment burden while maintaining optimal vision outcomes by enabling the continuous delivery of a customized formulation of ranibizumab into the vitreous. The PDS includes a permanent, refillable implant that ...Author: Peter A. Campochiaro, Dennis M. Marcus, Carl C. Awh, Carl Regillo, Anthony P. Adamis, Vladimir Bants...
https://www.gene.com/media/press-releases/14739/2018-07-25/genentech-unveils-positive-phase-ii-resu
Jul 25, 2018 · LADDER (Long Acting DElivery of Ranibizumab; NCT02510794) 6 is a Phase II study designed to evaluate the efficacy and safety of the Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD) who have previously responded to treatment with anti-vascular endothelial growth factor (VEGF) therapies. This ...
https://www.ncbi.nlm.nih.gov/pubmed/30946888
PURPOSE: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) treatment. DESIGN: Phase 2, multicenter, randomized, active treatment-controlled clinical trial.Author: Peter A. Campochiaro, Dennis M. Marcus, Carl C. Awh, Carl Regillo, Anthony P. Adamis, Vladimir Bants...
https://clinicaltrials.gov/ct2/show/NCT03677934
Sep 19, 2018 · A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been ...
https://www.retinalphysician.com/issues/2020/march-2020/port-delivery-of-ranibizumab
Mar 01, 2020 · The Port Delivery System with ranibizumab, or PDS (Genentech/Roche), has the potential to reduce the treatment burden for patients with neovascular AMD (nAMD) through continuous delivery of a customized formulation of ranibizumab.It has been tested in the LADDER clinical trial (NCT02510794), a phase 2 randomized controlled study, and recently the end-of-study results have been released.
https://eyewire.news/articles/genentech-roche-complete-enrollment-in-archway-phase-3-study-of-the-port-delivery-system-with-ranibizumab-in-wet-amd/
Genentech and Roche have completed patient enrollment in the phase 3 Archway (NCT03677934) clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD).The PDS is a first-of-its-kind refillable eye implant designed to continuously release a customized formulation of ranibizumab over a period of months.
https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bd94023a0-da11-4e37-94a0-ab173941d238%7D/genentech-completes-enrollment-in-ranibizumab-port-delivery-system-trial
Oct 20, 2017 · Enrollment has been completed in Genentech’s phase 2 clinical trial of the ranibizumab port delivery system implant in patients with wet age-related macular degeneration, according to a …
Searching for Port Delivery System Ranibizumab?
You can just click the links above. The data is collected for you.
